Search

everythinglearnresearchcommunity

for

Search:↓

The reasoning for GSK's approval of dutasteride for hair loss in Japan and South Korea but not the US, with alternatives such as finasteride, minoxidil and RU58841 mentioned.

AMP-303, a new injectable treatment for androgenetic alopecia, showed promising results in increasing hair count and density with minimal side effects. The treatment demonstrated significant hair regrowth and durability, offering new hope for those with hair loss.

The user reported significant hair improvement over 15 months using dutasteride, minoxidil (oral and topical), RU58841, ketoconazole, and microneedling. They are considering a hair transplant in 4-6 months.

RU58841, a potential hair loss treatment, was not commercialized due to marketability issues and lack of long-term safety data. Concerns about its formulation and delivery methods further complicate its use.

Finasteride can impact neurosteroids, potentially causing depression and other side effects in some users. Despite these concerns, many continue using it for hair loss, with some switching to topical applications to mitigate side effects.

A user is participating in a phase 3 trial for Clascoterone, a topical acne medication that may stimulate hair growth, and will share results after 6 months. They will have a section of their hair shaved and marked with a tattoo for the study.

A user shared their 2-month hair growth progress using only Minoxidil, noting significant improvement and plans to continue despite a genetic predisposition to baldness. They apply Minoxidil twice daily, experienced a heat rash, and chose not to use Finasteride due to side effects.

The conversation discusses the effects of finasteride on hair loss and its potential neurological and sexual side effects. Users share personal experiences, with some reporting positive outcomes and others expressing concerns about cognitive function.

A user shared a 6-month hair loss treatment routine including Mexican finasteride (1.25mg every other day), daily minoxidil, bi-weekly dermarolling, and ketoconazole shampoo twice a week, noting significant crown growth and some frontal hairline improvement with initial side effects that have since subsided. They are seeking advice to improve results, particularly at the frontal hairline, without resorting to a hair transplant.

Some individuals taking finasteride for hair loss report increased libido and frequent masturbation, with no immediate hair regrowth but darker hair appearance. A dermatologist explains that finasteride may raise testosterone levels temporarily, which could lead to increased sex drive in some people.

The conversation discusses the lack of significant advancements in hair loss treatments beyond finasteride and minoxidil, questioning if hair restoration technology has reached a dead end. Hair transplant technology has improved, but new medications face challenges with market entry, cost, accessibility, and long-term effectiveness.

A user who was part of an ongoing trial for a prolactin blocker and had regrowth, but the progress photos were not shared due to negative reactions from other users. Treatments mentioned include HMI-115, Minoxidil, Finasteride, and RU58841.

Hope Medicine's announcement of the HMI-115 Phase II clinical trial for androgenetic alopecia in China; other related trials have been conducted or are ongoing in different countries, including Australia, US, and Europe. There is speculation that the product may be accepted across borders without additional testing.

Pyrilutamide Phase 3 approved, starting early 2022 with 416 subjects for 24 weeks. Drug potentially better than RU and Breezula, with some users reporting no side effects.

KX-826 hair loss treatment completed trials with mild side effects. GT20029 may be ultimate cure, destroying androgen receptors causing baldness.

High cost of studying 3α-Hydroxysteroid dehydrogenase in hair loss led to suggestions of crowdfunding for research. Users discussed using Procyanidin B2/melatonin topical treatment and tracking funds with blockchain.

The post and conversation are about the long-term side effects of using Dutasteride and Finasteride for hair loss, including issues like raised liver enzymes, high cholesterol, and loss of libido. The user advises regular blood work and careful monitoring for those using these treatments.

The conversation discusses the use of RU58841, a non-FDA approved research chemical for hair loss, with mixed opinions on its safety and effectiveness. Some users are willing to try it as a last resort after other treatments like Minoxidil and Finasteride failed, while others express concerns about potential long-term side effects and lack of official research.

Topical finasteride is considered a safer option for hair regrowth with fewer systemic side effects compared to oral finasteride. Some users report similar efficacy and side effects between topical and oral treatments, while others prefer topical due to reduced systemic exposure.

The conversation discusses Kintor's initiation of a new Phase 3 trial to assess the long-term safety of Pyrilutamide (KX-826) for hair loss, which will last 52 weeks. Specific treatments mentioned include Pyrilutamide.

Ketoconazole is somewhat effective for male pattern baldness (MPB), but the manufacturer promotes it for dandruff instead, possibly because the dandruff market is larger and to avoid confusion among dandruff sufferers without hair loss.

The user wants to reduce their dose of topical finasteride to 0.1-0.2mg and is considering mixing 0.2ml of their current finasteride + minoxidil serum with 0.8ml of a minoxidil-only serum for better scalp coverage. They are asking for advice on whether this method is effective or if there's a better way to dilute the finasteride solution.

Hair loss discussion mentions HMI-115 efficacy in 3 months after Phase II study. Users discuss treatment effectiveness and mention massive regrowth in previously bald areas.

A Phase 1 update for the HMI 115 clinical trial, which involves 16 participants and is expected to end in July 2023; as well as changes to the recruitment process, including treatment protocols with Minoxidil, Finasteride, and RU58841.

Pyrilutamide, a nonsteroidal antiandrogen drug under development for the potential treatment of androgenic alopecia. The conversation discusses its binding affinity to the androgen receptor and the timeline for possible availability after trials are completed in the United States and China.

User LateNightCoffeeShop shared progress after 3 months using Finasteride, Minoxidil, and Derma-rolling for hair regrowth. Users discussed treatment frequency, effectiveness, and potential side effects.

A 20-year-old male's significant hair growth after two months of using 0.25mg Finasteride. The discussion includes varying opinions on the effectiveness and side effects of the treatment, with some users planning to try or adjust their Finasteride dosage.

Potential side effects of 5AR inhibitors like finasteride and dutasteride. Users debate risks, benefits, and personal experiences with these hair loss treatments.

People are discussing hair loss treatments and expressing hope for future hair cloning. Some mention using Minoxidil, finasteride, and RU58841.

A user shared their 3-month hair regrowth progress using 1mg finasteride, 5% minoxidil, and ketoconazole shampoo. Commenters noticed improvement and discussed the importance of waiting 6 months for more significant results.